Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-10-12
Based on 1082 first isolates · ED · Febrile UTI / pyelonephritis · 2024-10-13 → 2025-10-12
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
piperacillin-tazobactam 81 % (78 %–83 %)
Keep for severe or hospital-onset infections.
Not covered: Enterococcus faecalis (10 %), Staphylococcus aureus (3 %), Escherichia coli (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli not for this site
85 %
79 %
n = 81
meropenem MEM
trend · Escherichia coli reserve
84 %
85 %
n = 81
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
84 %
n = 81
ciprofloxacin CIP
trend · Escherichia coli
78 %
80 %
n = 81
mecillinam MEC
trend · Escherichia coli not for this site
77 %
74 %
n = 81
ceftriaxone CRO
trend · Escherichia coli
75 %
77 %
n = 81
trimethoprim TMP
trend · Escherichia coli not for this site
73 %
73 %
n = 81
71 %
73 %
n = 81
54 %
56 %
n = 81
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
11 %
n = 81
6 %
6 %
n = 81
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
2 %
n = 81

Most likely organisms for this profile

Escherichia coli
57 %
Enterococcus faecalis
10 %
Klebsiella pneumoniae
10 %
Pseudomonas aeruginosa
6 %
Proteus mirabilis
6 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.